ARTICLE | Company News
Micrologix, Hybridon HPV deal
September 12, 2002 7:00 AM UTC
Micrologix (TSE:MBI; MGXIF) acquired an exclusive, worldwide license to HYBN's IP covering a number of antisense oligonucleotides targeting human papillomavirus (HPV). MGI also acquired non-exclusive rights to a portfolio of HYBN antisense chemistries. Separately, MBI acquired rights to HYBN's ORI 1001, an HPV antisense compound. ...